Blue Jet Healthcare shareholders approve Re 1.20 dividend and key appointments
- Shareholders approved a dividend of Re 1.20 per share for FY26 with over 99% support
- All six resolutions from the 58th AGM were passed by requisite majority
- Public institutions voted against director re-appointments with ~1.26 million votes
- Promoter group voted unanimously in favor of all agenda items

*this image is generated using AI for illustrative purposes only.
Blue Jet Healthcare shareholders approved a dividend of Re 1.20 per equity share for FY26 during the 58th annual general meeting held on September 21, 2026. The payout received near-unanimous support, with over 99% of votes polled in favor.
The meeting, conducted via video conferencing and presided over by Chairman Akshay Bansarilal Arora, saw the adoption of audited standalone financial statements for the year ended March 31, 2026. The auditors' report contained no qualifications or adverse remarks.
Voting Results and Key Resolutions
All proposed resolutions were passed by requisite majority. The dividend declaration secured 148,697,767 votes in favor against just 8 votes against. Promoters and the promoter group, holding 138,445,726 shares, voted unanimously in favor of all agenda items.
Ordinary resolutions approved the re-appointment of Mr. Naresh Suryakant Shah as a director retiring by rotation and M/s. KKC & Associates LLP as statutory auditors. Special resolutions authorized the re-appointment of Akshay Bansarilal Arora as whole-time director and executive chairman, and Shiven A. Arora as managing director.
Scrutinizer Report and Participation
Ms. Nupur Gadekar, Partner at Mehta & Mehta, served as the scrutinizer for the e-voting process facilitated by MUFG Intime India Private Limited. Remote e-voting was open from September 18 to September 20, 2026.
| Resolution | Votes in Favour | Votes Against | Result |
|---|---|---|---|
| Adopt Financial Statements | 148,697,680 | 95 | Passed |
| Declare Dividend (Re 1.20) | 148,697,767 | 8 | Passed |
| Re-appoint Naresh S. Shah | 147,438,610 | 1,258,563 | Passed |
| Re-appoint KKC & Associates | 148,697,680 | 95 | Passed |
| Re-appoint Akshay B. Arora | 147,436,636 | 1,260,537 | Passed |
| Re-appoint Shiven A. Arora | 147,436,636 | 1,260,537 | Passed |
What the Numbers Show
The voting data reveals a significant divergence in shareholder sentiment between routine administrative items and leadership appointments. While the dividend and financial statement adoption attracted minimal opposition (less than 100 votes against), the re-appointment of directors Akshay Bansarilal Arora and Shiven A. Arora faced approximately 1.26 million votes against, primarily from public institutions. This suggests that while public institutional investors supported the company's financial health and dividend policy, they expressed reservations regarding the specific terms or continuity of the promoter-led management structure.
Historical Stock Returns for Blue Jet Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.54% | -3.25% | -8.42% | +29.32% | -21.57% | +25.94% |
How might the 1.26 million dissenting votes from public institutions influence Blue Jet Healthcare's future corporate governance reforms or board independence initiatives?
Will the unanimous promoter support for the dividend policy signal a commitment to maintaining high payout ratios in FY27, or is this a one-time distribution?
What specific concerns regarding the Arora family's leadership terms drove institutional investors to vote against the re-appointment of the Executive Chairman and Managing Director?


































